https://orcid.org/0000-0002-1453-4455
References
- Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.
- Almasi-Hashiani A, Sahraian MA, Eskandarieh S. Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999-2018. BMC Neurol. 2020;20(1):169.
- Acquaviva M, Menon R, Di Dario M, et al. Inferring multiple sclerosis stages from the blood transcriptome via machine learning. Cell Rep Med. 2020;1(4):100053.
- Bross M, Hackett M, Bernitsas E. Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis. IJMS. 2020;21(12):4312.
- Mahurkar S, Moldovan M, Suppiah V, et al. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics J. 2017;17(4):312–318.
- Harris VK, Tuddenham JF, Sadiq SA. Biomarkers of multiple sclerosis: current findings. Degener Neurol Neuromuscul Dis. 2017;7:19–29.
- Ventola CL. Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. P T. 2013;38(9):545–560.
- García-Gutiérrez MS, Navarrete F, Sala F, et al. Biomarkers in psychiatry: Concept, definition, types and relevance to the clinical reality. Front Psychiatry. 2020;11:432
- Coyle PK. Pharmacogenetic biomarkers to predict treatment response in multiple sclerosis: Current and future perspectives. Mult Scler Int. 2017;2017:6198530.
- Karam RA, Rezk NA, Amer MM, et al. Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy. IUBMB Life. 2016;68(9):727–734.
- Clarelli F, Liberatore G, Sorosina M, et al. Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis. Pharmacogenomics J. 2017;17(1):84–91.
- Peroni S, Sorosina M, Malhotra S, et al. A pharmacogenetic study implicates NINJ2 in the response to interferon-β in multiple sclerosis. Mult Scler. 2020;26(9):1074–1082.
- Noroozi R, Azari I, Taheri M, et al. A single nucleotide polymorphism within ninjurin 2 is associated with risk of multiple sclerosis. Metab Brain Dis. 2019;34(5):1415–1419.
- Filipi M, Jack S. Interferons in the treatment of multiple sclerosis: a clinical efficacy, safety, and tolerability update. Int J MS Care. 2020;22(4):165–172.
- Gezmis H, Doran T, Domac SFM, et al. Interferon-beta changes the expression of IL10, IL23A and FOXP3 on multiple sclerosis patients’ T cells. Authorea. 2021.
- Chang K-L, Weitzel K, Schmidt S. Pharmacogenetics: using genetic information to guide drug therapy. Am Fam Physician. 2015;92(7):588–594.
- Soilu-Hänninen M, Laaksonen M, Hänninen A, et al. Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS. J. Neuroimmunol. 2005;167(1-2):175–182.
- Araki T, Milbrandt J. Ninjurin2, a novel homophilic adhesion molecule, is expressed in mature sensory and enteric neurons and promotes neurite outgrowth. J Neurosci. 2000;20(1):187–195.
- Lin KP, Chen SY, Lai LC, et al. Genetic polymorphisms of a novel vascular susceptibility gene, Ninjurin2 (NINJ2), are associated with a decreased risk of alzheimer’s disease. PLoS One. 2011;6(6):e20573.